Novel Therapeutical Approaches to Managing Atherosclerotic Risk
Rosaria Vincenza Giglio,Anca Pantea Stoian,Khalid Al-Rasadi,Maciej Banach,Maciej Banach,Maciej Banach,Angelo Maria Patti,Marcello Ciaccio,Ali A. Rizvi,Ali A. Rizvi,Manfredi Rizzo,Manfredi Rizzo,Manfredi Rizzo +12 more
Reads0
Chats0
TLDR
A review of studies pertaining to cardiometabolic risk factors, lipids alterations, hypolipidemic agents, nutraceuticals, hypoglycaemic drugs, atherosclerosis, endothelial dysfunction, and inflammation was performed as mentioned in this paper.Abstract:
Atherosclerosis is a multifactorial vascular disease that leads to inflammation and stiffening of the arteries and decreases their elasticity due to the accumulation of calcium, small dense Low Density Lipoproteins (sdLDL), inflammatory cells, and fibrotic material. A review of studies pertaining to cardiometabolic risk factors, lipids alterations, hypolipidemic agents, nutraceuticals, hypoglycaemic drugs, atherosclerosis, endothelial dysfunction, and inflammation was performed. There are several therapeutic strategies including Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors, inclisiran, bempedoic acid, Glucagon-Like Peptide-1 Receptor agonists (GLP-1 RAs), and nutraceuticals that promise improvement in the atheromatous plaque from a molecular point of view, because have actions on the exposure of the LDL-Receptor (LDL-R), on endothelial dysfunction, activation of macrophages, on lipid oxidation, formations on foam cells, and deposition extracellular lipids. Atheroma plaque reduction both as a result of LDL-Cholesterol (LDL-C) intensive lowering and reducing inflammation and other residual risk factors is an integral part of the management of atherosclerotic disease, and the use of valid therapeutic alternatives appear to be appealing avenues to solving the problem.read more
Citations
More filters
Journal ArticleDOI
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
David Marais,Zeljko Reiner,Matteo Pirro,Manfredi Rizzo,Alexandros Sachinidis,Dan Gaita,Mohsen Mazidi,Daniel Pella,G.B. John Mancini,Stephan von Haehling,Maciej Banach,Julio Acosta,Mutaz Alkhnifsawi,Fahad Alnouri,Fahma Amar,Atanas G. Atanasov,G. Bajraktari,Sonu Bhaskar,Ibadete Bytyçi,Bojko Bjelakovic,Eric Bruckert,Alberto Cafferata,Richard Ceska,Arrigo F G Cicero,Xavier Collet,Magdalena Daccord,Olivier S. Descamps,Dragan Djuric,Ronen Durst,Marat V. Ezhov,Zlatko Fras,Adrian V. Hernandez,Steven P. Jones,Jacek Jerzy Jozwiak,N. Kakauridze,A. Kallel,Niki Katsiki,Amit Khera,Karam Kostner,Raimondas Kubilius,Gustavs Latkovskis,A. David Marais,Seth S. Martin,Julio A. Martínez,Dimitri P. Mikhailidis,Erkin M. Mirrakhimov,André R. Miserez,Olena Mitchenko,N.P. Mitkovskaya,Patrick M. Moriarty,Seyed Mohammad Nabavi,Devaki Nair,Demosthenes B. Panagiotakos,György Paragh,Peter E. Penson,Zaneta Petrulioniene,Arman Postadzhiyan,Raman Puri,Ashraf Reda,Dina Radenkovic,Michael Robert Rakowski,Jemaa Riadh,Dimitri Richter,Massimiliano Ruscica,Amirhossein Sahebkar,Naveed Sattar,Maria-Corina Serban,Abdullah Shehab,Aleksandr B Shek,Cesare R. Sirtori,Claudia Stefanutti,Tomasz Tomasik,Peter P. Toth,Margus Viigimaa,Pedro Valdivielso,Dragos Vinereanu,Branislav Vohnout,Michal Vrablík,Nathan D. Wong,Hung-I Yeh,Ji Zhisheng,Andreas Zirlik +81 more
TL;DR: A step‐by‐step patient‐centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long‐term compliance with lipid‐lowering therapy is presented.
Journal ArticleDOI
Hyperlipidemia and hypothyroidism
TL;DR: In this paper , the authors examined the relationship between hypothyroidism and the risk and pathologic development of hyperlipidemia and found that thyroid hormone plays an important role in cholesterol production, transformation and clearance.
Journal ArticleDOI
Insight into the Evolving Role of PCSK9
Mateusz Maligłówka,Michał Kosowski,Marcin Hachuła,Marcin Cyrnek,Łukasz Bułdak,Marcin Basiak,Aleksandra Bołdys,Grzegorz Machnik,Rafał J. Bułdak,Bogusław Okopień +9 more
TL;DR: Current knowledge on the roles that PCSK9 plays in different tissues and perspectives for its clinical use are summarized.
Journal ArticleDOI
Functional Crosstalk between PCSK9 Internalization and Pro-Inflammatory Activation in Human Macrophages: Role of Reactive Oxygen Species Release
Rafael I. Jaén,Adrián Povo-Retana,César Eduardo Rosales-Mendoza,Patricia Capillas-Herrero,Sergio Sánchez-García,Paloma Martín-Sanz,Marina Mojena,Patricia Prieto,Lisardo Boscá +8 more
TL;DR: New insights are provided into the role of PCSK9 in the crosstalk of lipids and cholesterol metabolism through the LDLR and on the pro-inflammatory activation of macrophages through TLR4 signaling, which are relevant in the outcome of atherosclerosis.
Journal ArticleDOI
Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus
TL;DR: In this paper , the effect of dulaglutide on the number and function of endothelial progenitor cells (EPCs) in the peripheral blood of patients with Type 2 diabetes mellitus (T2DM) and its role in improving arterial elasticity was investigated.
References
More filters
Journal ArticleDOI
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker,Brendan M. Everett,Tom Thuren,Jean G. MacFadyen,William Chang,Christie M. Ballantyne,Francisco H. Fonseca,Jose C. Nicolau,Wolfgang Koenig,Stefan D. Anker,John J.P. Kastelein,Jan H. Cornel,Prem Pais,Daniel Pella,Jacques Genest,Renata Cifkova,Alberto J. Lorenzatti,Tamás Forster,Zhanna Kobalava,Luminita Vida-Simiti,Marcus Flather,Hiroaki Shimokawa,Hisao Ogawa,Mikael Dellborg,Paulo Roberto Ferreira Rossi,Roland P.T. Troquay,Peter Libby,Robert J. Glynn +27 more
TL;DR: Antiinflammatory therapy targeting the interleukin‐1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid‐level lowering.
Journal ArticleDOI
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine,Robert P. Giugliano,Anthony C Keech,Narimon Honarpour,Stephen D. Wiviott,Sabina A. Murphy,Sabina A. Murphy,Julia F Kuder,Julia F Kuder,Huei Wang,Thomas Liu,Scott M. Wasserman,Peter S. Sever,Terje R. Pedersen,Terje R. Pedersen +14 more
TL;DR: In this trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.
Journal ArticleDOI
Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression
TL;DR: Transcriptome profiling reveals novel molecules and signatures associated with human monocyte-to-macrophage differentiation and polarized activation which may represent candidate targets in pathophysiology.
Journal ArticleDOI
Alirocumab and cardiovascular outcomes after acute coronary syndrome
TL;DR: Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than amongThose who received placebo.
Journal ArticleDOI
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson,Michel Farnier,Michel Krempf,Jean Bergeron,Gérald Luc,Maurizio Averna,Erik S.G. Stroes,Gisle Langslet,Frederick J. Raal,Mahfouz El Shahawy,Michael J. Koren,Norman E. Lepor,Christelle Lorenzato,Robert Pordy,Umesh Chaudhari,John J.P. Kastelein +15 more
TL;DR: Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels and there was evidence of a reduction in the rate of cardiovascular events.